Coronavirus (COVID-19)
Learn more
April 26, 2017
Sponsor: Gynecologic Oncology Group
Number: 3005/ABBVIE M13-694
The focus of this study is to evaluate the efficacy, safety, and tolerability of Veliparib in women with previously untreated, Stage III or IV (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer), high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Who’s eligible:
Available at: The Hospital of Central Connecticut.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.